Literature DB >> 8438086

Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

M Höckel1, C Knoop, K Schlenger, B Vorndran, E Baussmann, M Mitze, P G Knapstein, P Vaupel.   

Abstract

Experimental evidence suggests that the hypoxic fraction in a solid tumor may increase its malignant potential and reduce its sensitivity towards non-surgical treatment modalities (e.g. standard irradiation, certain anticancer agents). However, the clinical importance of tumor hypoxia remains uncertain since valid methods for the routine measurement of intratumoral O2-tensions in patients have so far been lacking. A clinically applicable standardized procedure has been established which enables the determination of intratumoral oxygen tensions in advanced cervical cancers by use of a computerized polarographic needle electrode histography system. Tumor oxygenation as measured by this method represents a novel tumor feature which can be individually determined for each tumor and which is independent from other known oncological parameters. The results of an interim analysis of an open prospective clinical trial to evaluate the prognostic significance of tumor oxygenation based on the survival data of the first 31 patients are presented. Fifteen patients have been treated by primary radiation, 11 patients received multimodality therapy including irradiation. After a median follow-up of 19 months (range 5-31 months), Kaplan-Meier-life table analysis showed significantly lower survival and recurrence-free survival for patients with a median pO2 of < or = 10 mmHg compared to those with better oxygenated tumors (median pO2 > 10 mmHg). The Cox proportional hazards model revealed that the median pO2 and the clinical stage according to the FIGO are independent, highly significant predictors of survival and recurrence-free survival. We conclude from these preliminary results that tumor oxygenation as determined with this standardized procedure appears to be a new independent prognostic factor influencing survival in advanced cancer of the uterine cervix.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438086     DOI: 10.1016/0167-8140(93)90025-4

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  179 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Molecular biology: the key to personalised treatment in radiation oncology?

Authors:  D G Hirst; T Robson
Journal:  Br J Radiol       Date:  2010-09       Impact factor: 3.039

3.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

Review 4.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

5.  Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

Authors:  Tetsuhiro Tanaka; Toshio Miyata; Reiko Inagi; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host.

Authors:  Tetsuhiro Tanaka; Junna Yamaguchi; Kumi Shoji; Masaomi Nangaku
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

Review 7.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

8.  Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.

Authors:  Wenli Wang; Nancy Y Lee; Jens-Christoph Georgi; Manoj Narayanan; Jose Guillem; Heiko Schöder; John L Humm
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

9.  Oxymetry deep in tissues with low-frequency electron paramagnetic resonance.

Authors:  H J Halpern; C Yu; M Peric; E Barth; D J Grdina; B A Teicher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 10.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.